Completed NA INTERVENTIONAL 2-arm NCT04793984

Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients

Sponsor: Marinomed Biotech AG

Conditions Covid19

Updated 4 times since 2021 Last updated: Aug 24, 2022 Started: Mar 8, 2021 Primary completion: Jul 30, 2022 Completion: Jul 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04793984, this NA trial focuses on Covid19 and remains completed. Sponsored by Marinomed Biotech AG, it has been updated 4 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2022 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Apr 2021 — Sep 2022 [monthly]

Recruiting NA

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marinomed Biotech AG

Data source: Marinomed Biotech AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria